Skip to main

Omnix Medical raises $25 million Series C to tackle drug-resistant infections

15 Oct 2025

Israeli biotech secures funding to complete Phase II trials for its novel antimicrobial peptide therapy.

Category:
Sub Categories:
Share this article on social media
To read the full article, visit CTech websitehttps://www.calcalistech.com/ctechnews/article/hjqrmrnpgl website
© All rights reserved to IVC and Israel Innovation Authority
Disclaimer:
The information provided on this platform is based solely on publicly available sources collected from the internet, including news articles, press releases, company websites, and other open-access materials.
The content is provided "AS IS" for informational purposes only and should not construed as professional, legal, or investment advice.
While we strive to ensure the accuracy and timeliness of the information presented, we do not guarantee its completeness or correctness.
Users are encouraged to independently verify any data before relying on it.
IVC shall bear no liability for investment decisions based on the information provided. In no event shall IVC or its employees, agents, or affiliates be liable for any direct, indirect, actual, special, or consequential damages resulting from the use of the information provided.